Lymphoma Clinical Trials

Showing 641-660 of 1,633 trials

Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis

NCT04758650

Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with oncological lesions in need of non-surgical therapy, patients with cardiovascular atherosclerosis, syndrome with abnormal immune activation and sarcoïdosis.

Solid Malignancy Located in the Head and NeckCancerCarotid Stenosis+6 more

Universitair Ziekenhuis Brussel140 participantsStarted Jan 2021

Brussels, Brussels Capital, Belgium

RECRUITINGPHASE1

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

NCT06136364

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.

T-lymphoblastic LymphomaT-ALL

Hebei Senlang Biotechnology Inc., Ltd.9 participantsStarted Aug 2023

Shanghai, China

UNKNOWN

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

NCT04870853

This study characterizes cardiac events following standard of care chimeric antigen receptor T cell therapy in patients with aggressive B-Cell Lymphoma that has come back (relapsed) or does not respond to treatment (refractory). The results from this study may allow a description of these events, their managements and outcome.

Recurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+7 more

M.D. Anderson Cancer Center150 participantsStarted Apr 2020

Houston, Texas, United States

Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Related Searches

REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

Use of GnRHa During Chemotherapy for Fertility Protection

Brentuximab for Newly Diagnosed Hodgkin Disease

MabionCD20 Compared to MabThera in Lymphoma Patients

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

L19IL2/L19TNF in Skin Cancer Patients

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

National Registry of Rare Kidney Diseases

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery

Transplantation After Complete Response In Patients With T-cell Lymphoma

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma